Dublin-based biotech Aerska has emerged from stealth mode with $21 million in seed funding to develop antibody-oligonucleotide conjugates (AOCs) designed to deliver RNA interference therapies across the blood-brain barrier to treat neurological disorders. The company prioritizes genetic forms of Alzheimer’s and Parkinson’s diseases for early validation. Investors include Age1, Backed VC, and others. Aerska aims to overcome current CNS drug delivery barriers, addressing a critical unmet need in neurodegenerative disease therapeutics. The funding supports preclinical milestones and candidate nomination.